Pfizer PE Ratio 2006-2018 | PFE

Current and historical PE ratio for Pfizer (PFE) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Pfizer (PFE) as of March 31, 2018 is 13.69.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.417B $52.546B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.885B 16.15
Novartis AG (NVS) Switzerland $187.250B 16.06
Merck (MRK) United States $168.539B 15.06
AbbVie (ABBV) United States $142.740B 14.56
Novo Nordisk (NVO) Denmark $121.712B 20.17
Sanofi (SNY) France $105.114B 13.31
GlaxoSmithKline (GSK) United Kingdom $100.888B 13.79
Eli Lilly (LLY) United States $97.070B 19.27
AstraZeneca (AZN) United Kingdom $93.793B 9.82
Bristol-Myers Squibb (BMY) United States $92.417B 18.18